Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedU.S. GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in US dollars).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Operating revenue increased due to a change in the estimate used to measure progress toward satisfaction of the performance obligations and the service period being 1 quarter longer. Research and development and patent costs decreased due to lower MN-166-related expenses and MN-001 clinical trial expenses. General and administrative expenses increased due to higher professional fees and share-based compensation expense.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | U.S. GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | 645,423 US dollars |
| Operating profit | -5,376,995 US dollars |
| Ordinary income | -4,900,397 U.S. dollars (pretax interim net income) |
| Profit attributable to owners of the parent | -4,900,397 US dollars |
| Net income per share | ¥△16 |
| Equity ratio | End of the current fiscal period 92.2% / End of previous period 91.2% |
| Total assets | 40,433,469 US dollars |
| Net assets | 37,270,602 US dollars |
| Cash flows from operating activities | -5,390,262 US dollars |
| Cash flows from investing activities | -10,825 US dollars |
| Cash and cash equivalents at end of period | 25,415,921 US dollars |
| Annual Dividend Forecast | 0.00 U.S. dollars per share → 0.00 U.S. dollars per share（0%） |
| Depreciation and amortization | 9,280 US dollars |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Not disclosed / Other changes Not disclosed / Change in accounting estimate Yes (change in the estimate used to measure progress toward satisfaction of the performance obligations) / Restatement Not disclosed |
| Issued Shares at Period-End | 49,221,246 shares |
| Factors Behind Changes in Business Performance | Operating revenue increased due to a change in the estimate used to measure progress toward satisfaction of the performance obligations and the service period being 1 quarter longer. Research and development and patent costs decreased due to lower MN-166-related expenses and MN-001 clinical trial expenses. General and administrative expenses increased due to higher professional fees and share-based compensation expense. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in operating revenue was attributable to a change in the estimate used to measure progress toward satisfaction of the performance obligations under the contract with the Mayo Foundation, as well as the service period being 1 quarter longer than in the same period of the previous year. The narrowing of the operating loss was primarily due to lower research and development and patent costs, reflecting decreases of $1.5 million in MN-166-related research expenses and $0.2 million in MN-001 clinical trial expenses.